Abstract 15142: Unraveling the Gene Architecture of the Sub-Diagnostic HCM 'Gray-Zone'
Abstract
Background: Hypertrophic Cardiomyopathy (HCM) is diagnosed by unexplained left ventricular hypertrophy (LVH) ≥15mm. This threshold is unadjusted for age and sex, contributing to diagnostic uncertainty for unexplained hypertrophy in the sub-diagnostic ‘gray-zone’ (≥12 to <15 mm). We characterized the genetic architecture of gray-zone LVH and compared clinical features and outcomes between carriers and non-carriers of rare variants in HCM-associated or HCM-genocopy genes. Methods: The Royal Brompton (RBH) Biobank prospectively enrolled 6,548 patients referred for diagnostic Cardiac Magnetic Resonance (CMR) imaging. Subjects with gray-zone LV maximum wall thickness (LVMWT ≥12 <15mm) were included, excluding those aged <16 years, with >mild aortic stenosis, a confirmed HCM phenocopy (e.g. infiltrative or syndromic LVH), a known family history of HCM, or isolated apical hypertrophy (where alternative criteria apply). Patients underwent genetic sequencing, and were assessed for rare (protein altering, allele frequency < 1 in 1000) variants in 28 genes with strong/definitive evidence for HCM or other genetic causes of LVH. Results: In total, 270 patients with gray-zone LVH were identified (mean age 58.3±13.9 years; male 79.6%; European ancestry 83.7%; LVMWT 12.9±0.8mm; hypertensive 53.0%; diabetic 13.3%), of whom 230 underwent genetic analysis. Over a median follow-up of 11.37 years [IQR 10.19-12.73] there were 44 deaths. Patients were most commonly referred for evaluation of possible cardiomyopathy (n=133, 57.8%), ischemia (n=32, 13.9%) or ventricular dysfunction (n=28, 12.2%). A rare variant (allele frequency <1 in 1000) in an HCM/LVH-associated gene was present in 18.3% (n=42), but only 2.6% carried a variant reported as pathogenic/likely pathogenic (P/LP) in ClinVar (n=6: MYBPC3=2, TTR=2, MYH7=1, TNNI3=1). Carriers and non-carriers did not differ in age, sex, hypertension history or CMR features (LVMWT, LVEF, LV volumes, late gadolinium enhancement); diabetes was less common in carriers (2.4% vs 16%, P=0.02). Rare-variant carriage did not predict all-cause mortality (HR 1.03, 95% CI 0.46-2.32) after adjustment for age and sex. In a subset without hypertension (n=109/230), 5 (4.6%) carried a P/LP variant. A personalized LVH threshold (adjusted for age, sex and body surface area) reclassified 27 (24.8%) as having demographically-adjusted LVH but did not improve P/LP yield (3.7%, n=1). Conclusion: In this referral cohort with ‘gray-zone’ LVH (≥12 to <15mm), rare-variant carriage was relatively common (18.3%) but confirmed P/LP variants were uncommon (2.6%), and carriage did not predict all-cause mortality. Demographically-adjusted LVH thresholds did not materially improve genetic yield, suggesting that escalation of genetic testing or diagnostic re-labeling in gray-zone LVH should not rely on wall thickness alone but be guided by other associated risk factors.